» Articles » PMID: 11308009

Treatment of Severe Acute Respiratory Distress Syndrome: a Final Report on a Phase I Study

Overview
Journal Am Surg
Specialty General Surgery
Date 2001 Apr 20
PMID 11308009
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Adult respiratory distress syndrome (ARDS) has a high mortality. Its only effective treatment is respiratory therapy. If this fails mortality is probably 100 per cent. No other treatment for ARDS has proved effective including "magic bullets." Twenty patients suffering from ARDS secondary to trauma and/or sepsis failed to respond to treatment with mechanical ventilation and positive end-expiratory pressure. On the assumption that disseminated intravascular coagulation initiates ARDS by occluding the pulmonary microcirculation with microclots, the patients were treated with plasminogen activators. The patients responded with significant improvement in partial pressure of oxygen in arterial blood. No bleeding occurred and clotting parameters remained normal. We conclude that ARDS can be safely treated with plasminogen activator.

Citing Articles

Alteplase in COVID-19 severe hypoxemic respiratory failure: the TRISTARDS multicenter randomized trial.

Landoni G, Chowdary P, Meziani F, Creteur J, De Schryver N, Motsch J Ann Intensive Care. 2024; 14(1):170.

PMID: 39522090 PMC: 11551089. DOI: 10.1186/s13613-024-01386-z.


All tangled up: interactions of the fibrinolytic and innate immune systems.

Whyte C Front Med (Lausanne). 2023; 10:1212201.

PMID: 37332750 PMC: 10272372. DOI: 10.3389/fmed.2023.1212201.


Systemic thrombolytics as rescue therapy for COVID-19 patients with acute respiratory distress syndrome: A retrospective observational study.

Ashwathappa P, Jacob I, Rangappa P, Rao K Int J Crit Illn Inj Sci. 2023; 12(4):197-203.

PMID: 36779209 PMC: 9910116. DOI: 10.4103/ijciis.ijciis_45_22.


Fibrinolytic therapy in patients with COVID-19 and ARDS: protocol for a systematic review and meta-analysis.

Savioli F, Ribeiro Dos Santos L, Duarte M, Carmo A, Gois A, Nakano L BMJ Open. 2023; 13(1):e066623.

PMID: 36593003 PMC: 9808755. DOI: 10.1136/bmjopen-2022-066623.


Effectiveness and safety of fibrinolytic therapy in critically ill patients with COVID-19 with ARDS: protocol for a prospective meta-analysis.

Kovacs E, Dembrovszky F, Ocskay K, Szabo L, Hegyi P, Molnar Z BMJ Open. 2022; 12(9):e063855.

PMID: 36167378 PMC: 9515457. DOI: 10.1136/bmjopen-2022-063855.